Glicosilceramidas

Otros Nombres

Ceramide monohexosideCeramide monohexosidesCeramide-galactoseCeramide-glucoseCerebrosideCerebrosidesCMHGalactocerebrosideGalactosylceramideGalCerGlcCerGlucocerebrosideGlucopsychosine ceramideGlucosylceramideGlycosphingolipidGlycosphingolipidsGlycosylceramideGSLMonogalactosylceramideMonoglucosylceramideMonoglycosylceramideMonoglycosylceramidesMonohexosylceramideMonohexosylceramidesNeutral glycolipidNeutral glycosphingolipidOligoglycosylceramidePolyglycosylceramideSphingoglycolipidSugar ceramideβ-Galactosylceramideβ-Glucosylceramide

Sinopsis

Glycosylceramides: A Comprehensive Reference

1. Identity: Chemical Names, Natural Sources, and Common Forms

1.1 Chemical Identity

Glucosylceramide (GlcCer) is composed of a long-chain base (LCB) with an amide-linked fatty acid (i.e., ceramide) and a polar head group (i.e., glucose), representing one class of sphingolipids, and is found naturally in plant-derived foods. In broader terminology, the class is called glycosylceramides (GlyCer), which encompasses all ceramides bearing one or more sugar residues. Sphingolipids consist of sphingoid bases, sphingosine-1-phosphate, ceramides, phosphodiester-bound complex sphingolipids, and glycosyl-bound complex sphingolipids such as glucosylceramide, galactosylceramide, and glycosylsphingolipids. Glucosylceramide is specifically a sphingolipid composed of a sugar moiety and a ceramide.

The two principal forms encountered as dietary supplement ingredients are:

Glucosylceramide (GlcCer) — the dominant form in plant and fungal tissue, bearing a single glucose head group. Also called glucocerebroside.
Galactosylceramide (GalCer) — the dominant form in animal nervous tissue, bearing a galactose head group. Less common as a supplement ingredient.

In the dietary supplement literature, plant-derived glucosylceramides are widely marketed under the term phytoceramides. Phytoceramides are plant-derived ceramides extracted predominantly from rice, wheat, konjac, and peach sources; in their natural plant form they exist as glucosylceramides — ceramides with a glucose molecule at the head group — rather than as free ceramides.

1.2 Structural Characteristics

Plant-derived glucosylceramides are structurally distinct from their mammalian counterparts. Plant sphingolipids differ structurally from those of mammals: soy glucosylceramide consists predominantly of a 4,8-sphingadiene backbone and α-hydroxy-palmitic acid. Soybean GlcCer is comprised primarily (>98%) of ceramide with 4,8-sphingadiene (d18:2(Δ4,Δ8)) and α-hydroxypalmitic acid (h16:0), while wheat GlcCer has three major ceramide species: d18:2(Δ4,Δ8) with h16:0, d18:1(Δ8) with h16:0, and d18:2(Δ4,Δ8) with h20:0, with smaller amounts of other homologs.

The fatty acid components of plant glucosylceramides are not very different in nature from those in animal tissues, comprising mainly longer-chain saturated and monoenoic acids, with a high proportion being saturated and having a hydroxyl group in position 2. Both di- and tri-hydroxy long-chain bases have been found, mainly diunsaturated and almost entirely C18 in chain-length. The most abundant class of sphingolipids in plant tissue are mono-glucosylceramides, which are mostly characterized by a double bond at position 8 on the sphingoid residues and α-hydroxy fatty acids.

1.3 Natural Food Sources

Glucosylceramide is a major sphingolipid of plant tissue and, thus, abundant in nature and in dietary food sources. Glucosylceramides are found in various plants, such as rice, konjac, wheat, and pineapple, and ceramides have also been identified in soy sauce lees and citrus peel. The simplest and predominant sphingolipid form in plants are glucosylceramides, with a single glucose head group; they are commercially available from legumes such as soya and cereals such as rice and wheat, which are consumed by the majority of the world population.

Additional sources identified in the scientific literature include:

Fungi and fermented foods: Glycosylceramides are among the abundant glycosphingolipids in Aspergillus and are known to improve skin barrier function and prevent intestinal impairment as a prebiotic. Some filamentous fungi of Aspergillus spp., synthesizing both GlcCer and GalCer, represent an amenable source to exploit glycosylceramides as moisturizing ingredients or dietary supplements.
Marine invertebrates: Chemical examination of the sea cucumber Holothuria leucospilota led to the isolation of a phytosphingosine-type glucocerebroside with a 2-hydroxylated fatty acid of 22 carbons.
Legumes (lupin, mung bean): Plants less commonly consumed as food, such as lupin and naked barley, may provide an alternative economic advantage as sources of GlcCers.
Pollen: Much higher concentrations of glucosylceramides are found in pollen than in leaves, with substantial compositional differences.

1.4 Common Commercial Forms and Preparations

In commerce, glycosylceramides are offered in several standardized forms:

Wheat polar lipid complexes (WPLC): Lipid extracts from wheat flour standardized to a defined GlcCer content, available as powder or oil in capsule form.
Konjac extracts: Amorphophallus konjac is a rich source of glycosyl ceramides and glucomannan; konjac tuber-derived glycosylceramides have been commercially exploited as dietary supplements for dry skin.
Rice bran extracts: Standardized rice bran fractions, including proprietary products such as Oryza Ceramide®, provide glucosylceramides with co-present phytosterol glucosides.
Wine lees (sake lees) extracts: Fermentation by-products from wine and sake production that contain ceramides and glucosylceramides.
Topical cosmetic formulations: Glucosylceramides are incorporated into skin creams and lotions, though the primary supplement focus has been on oral delivery.

2. Traditional and Historical Use

As chemically defined compounds, glycosylceramides were not identified and named as such in pre-modern traditions; rather, the foods and preparations in which they are naturally abundant were used empirically for purposes now recognized as related to their sphingolipid content.

2.1 Konjac in East Asian Traditions

Konjac (Amorphophallus konjac) is used in Chinese folk medicine as a tumour suppressor, for detoxification, and for phlegm liquefaction; it is a rich source of glycosyl ceramides and glucomannan. In Japan, konjac (known as konnyaku) has been consumed for over a millennium as a food product — processed into gelatinous blocks, noodles, and snacks — and is an integral component of traditional Japanese cuisine and Buddhist vegetarian cooking. The plant's tuber contains meaningful concentrations of glucosylceramides, though these were not the recognized active component in historical traditions.

2.2 Rice and Wheat in Asian and European Traditions

Rice bran has been used therapeutically in East Asian traditional medicine systems and as a dietary staple throughout Asia. Wheat products have been dietary staples in Western and Middle Eastern traditions for millennia. Neither tradition explicitly attributed health effects to sphingolipid fractions, as the chemical understanding of these molecules did not emerge until the late 19th century (sphingomyelin was first described by J.L.W. Thudichum in 1884, and the glycosphingolipid family was characterized progressively throughout the 20th century).

2.3 Fermented Foods in Japan

The Japanese traditional dietary fungus koji (Aspergillus oryzae) functions as a prebiotic partly through its glycosylceramide content, acting via Blautia coccoides. Koji has been used in Japan for over a thousand years as the fermentation agent for sake, miso, soy sauce, and vinegar, and its regular consumption as a traditional food represents a historical route of dietary glycosylceramide intake, even if this was not contemporarily recognized.

2.4 Emergence as a Defined Supplement

Around 2000, the use of dietary sphingolipids for the prevention of colon cancer was reported; in the 2010s, an increase in skin barrier function due to dietary sphingolipids was reported. The commercial development of standardized glycosylceramide supplements — particularly from wheat, rice, and konjac — arose primarily from Japanese cosmetic and nutraceutical research in the 1990s and 2000s, making this ingredient primarily a product of the modern evidence-based dietary supplement era rather than of ancient traditional medicine.

3. Key Constituents and Mechanisms of Action

3.1 Endogenous Role in Human Skin

Before examining dietary effects, it is essential to understand the physiological role of glucosylceramides in human skin, which provides the mechanistic framework for evaluating supplementation. Mammalian epidermis produces and delivers large quantities of glucosylceramide and sphingomyelin precursors to stratum corneum extracellular domains, where they are hydrolyzed to corresponding ceramide species; this cycle of lipid precursor formation and subsequent hydrolysis represents a mechanism that protects the epidermis against potentially harmful effects of ceramide accumulation within nucleated cell layers.

Lamellar bodies contain predominantly glucosylceramides, phospholipids, and cholesterol; following the exocytosis of lamellar lipids into the extracellular space of the stratum corneum, these precursor lipids are converted by beta-glucocerebrosidase and phospholipases into the ceramides and fatty acids that comprise the lamellar membranes. Ceramides are the major component of the stratum corneum, accounting for 30–40% of stratum corneum lipids by weight; stratum corneum ceramides, together with cholesterol and fatty acids, form extracellular lamellae responsible for the epidermal permeability barrier.

Ceramide moieties of acylglucosylceramides and glucosylceramides correspond to stratum corneum ceramides 1–7; these results indicate that all ceramide species, including omega-hydroxy fatty-acid-containing ceramides, are derived from glucosylceramides.

3.2 Link to Atopic Dermatitis

A deficiency of ordinary ceramides in the stratum corneum is an essential etiologic factor for the dry and barrier-disrupted skin of patients with atopic dermatitis (AD); a novel sphingolipid metabolizing enzyme, termed SM-GlcCer deacylase, hydrolyzes sphingomyelin or glucosylceramide at the acyl site to yield lysoforms instead of ceramide, leading to ceramide deficiency in AD skin. Prominent skin disorders such as psoriasis and atopic dermatitis have diminished epidermal ceramide levels, reflecting altered sphingolipid metabolism that may contribute to disease severity and progression.

3.3 Absorption and Bioavailability After Oral Intake

Dietary glycosylceramides were found to metabolize in the rat small intestine: about half of the dietary substrate was absorbed and found in portal blood after hydrolysis by ceramidases in the gastrointestinal tract. Even though a large proportion of ingested sphingolipids are excreted in feces, animal studies reported that after oral intake, radiolabeled ceramides are metabolized, absorbed, and distributed to many tissues, including the skin.

Most of the ingested glucosylceramide is not degraded in the small intestine, and 50–90% of the glucosylceramide in the large intestine is excreted in feces. Plant-derived glucosylceramides are hydrolyzed into free sphingoid bases in the digestive tract before being absorbed into the lymph. Dietary ceramides and glucosylceramides can be absorbed as intact molecules or, after being hydrolyzed, as free sphingoid bases, which are then resynthesized into ceramides with endogenous non-hydroxy fatty acids.

One proposed mechanism is that trace amounts of absorbed degraded products of sphingolipids reach the skin and exert physiological effects; one criticism is that the absorption efficiency is low.

3.4 Proposed Mechanisms for Skin Benefit

The glucosylated form enables intestinal absorption through pathways unavailable to free ceramides, making phytoceramides one of the few genuinely evidence-supported routes to influencing skin ceramide status from within.

The tight junction mechanism has also been investigated at the cellular level: glycosylceramide purified from koji increases the expression of genes involved in tight junctions and ceramide delivery in normal human epidermal keratinocytes.

3.5 Intestinal Mechanisms

The majority of orally consumed glucosylceramide passes through the small intestine largely intact and enters the large intestine, where several mechanisms have been proposed:

Prebiotic activity: Glucosylceramide alters the metabolism of and production of lactic acid by Blautia coccoides, increases the ratio of Gram-positive bacteria, and endows tolerance to deoxycholic acid in certain bacteria such as Lactobacillus delbrueckii, Streptococcus mutans, Clostridium butyricum, Blautia coccoides, and Enterococcus faecalis.
Secondary bile acid modulation: Glucosylceramide endows intestinal microbes with tolerance to secondary bile acid.
Anti-cancer signaling: Glucosylceramide, which reduced tumor burden in the APCmin and DMH models, significantly alters the expression of 96 genes, including decreased expression of the TCF/LEF family member TCF4.

3.6 Anti-Allergy Mechanisms

Direct treatment of GlcCer on mast cells did not affect degranulation, but the sphingoid base moiety of pineapple-derived GlcCer did; these results indicate that the sphingoid base metabolite, through the intestine, inhibited type I hypersensitivity by inhibiting mast cell degranulation. The inhibitory effects were canceled by pretreatment with a leukocyte mono-immunoglobulin-like receptor 3 (LMIR3)-Fc, indicating involvement of LMIR3-mediated inhibitory signals.

4. Scientific Evidence by Area of Use

4.1 Skin Barrier Function and Hydration

This is by far the most extensively studied application for dietary glycosylceramides, with evidence progressing from animal models to multiple randomized controlled trials in humans.

Animal Evidence

In hairless mice, skin barrier functions impaired by chronic or acute perturbations were improved by dietary glucosylceramide. Additional hairless mice fed a diet with or without a maize-extracted glucosylceramide supplement for 5 weeks showed that the TEWL was significantly reduced at 2 weeks and the stratum corneum flexibility was increased at 3 weeks compared to controls.

Konjac — Human Randomized Clinical Trials

In a randomized, double-blind, placebo-controlled trial, 100 people with high TEWL in the cheeks were given placebo or konjac extract daily for 12 weeks; the extract group experienced significant improvement of TEWL, suggesting improved skin moisture retention, as well as reduction of skin itching.

In a separate placebo-controlled clinical trial assessing oral supplementation of a hydroalcoholic extract from Amorphophallus konjac tubers standardized to 5% glycosylceramides, 51 healthy human volunteers aged 18–60 years were supplemented with 100 mg/day of either placebo or the konjac extract capsules (providing 5 mg glycosylceramides) for 6 weeks; skin parameters were evaluated through dermatological diagnosis and self-assessment questionnaire. Oral intake of the konjac extract significantly decreased skin dryness, hyperpigmentation, redness, itching, and oiliness (p < 0.05).

Wheat-Derived Glucosylceramides — Human Randomized Clinical Trials

A placebo-controlled clinical study evaluated oral supplementation with glucosylceramides contained in a wheat polar lipids complex (WPLC) in 60 volunteers with dry and wrinkled skin, supplemented for 60 days with either a placebo or a WPLC extract in oil or powder form (1.7 mg GluCers and 11.5 mg of digalactosyldiglycerides per day); skin parameters were evaluated at baseline and after 15, 30, and 60 days. Oral intake of WPLC significantly increased skin hydration (p < 0.001), elasticity, and smoothness (p < 0.001), and decreased TEWL (p < 0.001), roughness (p < 0.001), and wrinkledness (p < 0.001) in both WPLC groups compared to placebo.

Wine Lees — Human Randomized Clinical Trial

A randomized, double-blind, placebo-controlled study conducted with 30 healthy Japanese subjects aged 20–64 was conducted in which subjects received either wine lees extract-derived ceramides and glucosylceramides (100 mg/day test supplement) or placebo for 12 weeks; the primary outcome was TEWL. After 8 weeks, the test group showed a tendency toward lower TEWL compared to placebo (p = 0.07). No significant differences were observed in the secondary outcome parameters; no adverse events related to the supplements were reported. The authors concluded that oral supplementation of wine lees extract-derived ceramides and glucosylceramides is a prominent and safe approach to enhancing skin barrier function and health.

Overall Assessment — Skin

The positive effect of oral supplementation with glucosylceramides on skin parameters is demonstrated and could reasonably reinforce the observations made on mice that orally-supplied sphingolipids can reach the skin. Overall, the evidence in this area comprises multiple small-to-moderate-sized randomized controlled trials, consistent in direction of effect, but with limitations including small sample sizes, short durations (6–12 weeks), heterogeneous populations and source materials, and the lack of large independent replications. The mechanistic pathway from oral intake to skin ceramide replenishment has biological plausibility but is not yet fully established.

4.2 Atopic Dermatitis

Dietary glucosylceramides have been reported to have an anti-inflammatory effect against atopic dermatitis and colitis, and to suppress mRNA expression of the proinflammatory cytokines interleukin-1β and interleukin-6.

A clinical observation study referenced in the literature (Kimata H, 2006, Pediatr Dermatol) found improvement of atopic dermatitis and reduction of skin allergic responses following oral intake of konjac ceramide, and a brief communication (Miyanishi K et al., 2005, Allergy) reported reduction of transepidermal water loss by oral intake of glucosylceramides in patients with atopic eczema. Ingestion of konjac ceramides has shown positive effects in atopic dermatitis patients as well as healthy volunteers, with results showing improved skin symptoms and reduced skin allergic responses. However, well-powered dedicated clinical trials specifically targeting atopic dermatitis are limited; the current evidence is preliminary and derives mainly from small or uncontrolled observations.

4.3 Colorectal and Gastrointestinal Cancer Prevention

Dietary glucosylceramide has been reported to prevent colon preneoplastic lesions, prevent head and neck cancers, inhibit colorectal cancer, inhibit throat cancer, inhibit inflammatory bowel disease (IBD), improve atopic dermatitis, maintain skin moisture, improve lipid metabolism, improve cholesterol metabolism, improve intestinal microbial flora, and relieve bile acid pressure. It is critical to note that these reports derive predominantly from animal or in vitro studies, not human clinical trials.

In animal studies, glucosylceramide, lactosylceramide, or ganglioside GD3 induced at least a 40% decrease in the number of aberrant crypt foci (an early marker of colon carcinogenesis), accompanied by a decrease of proliferation in the colonic crypts. There was no difference in the number of apoptotic cells per crypt among the different groups and the controls.

Soy glucosylceramide reduced colonic cell proliferation in the upper half of the crypts in DMH-treated mice by 50 and 56% (p < 0.05) at 0.025 and 0.1% of the diet, respectively, and reduced the number of aberrant colonic crypt foci by 38 and 52% (p < 0.05). Min mice fed diets containing 0.025 and 0.1% (wt/wt) soy GlcCer developed 22 and 37% fewer adenomas (p < 0.05), respectively.

Glucosylceramide (Glu-Cer), a glycosylated form of ceramide, has been reported to have cytotoxic effects in cells of various cancers; dietary glucosylceramide from rice bran had inhibitory effects on human head and neck squamous cell carcinoma (HNSCC) in NOD/SCID mice.

Critically: Neither human clinical trials nor epidemiologic studies have yet evaluated whether sphingolipids influence human colon cancer. Nonetheless, sphingosine and ceramide have been shown to induce apoptosis in human adenocarcinoma cell lines. The evidence for anti-cancer effects is limited to animal models and cell culture and cannot be extrapolated to humans.

4.4 Gut Microbiome and Intestinal Health

Glucosylceramide is present in many foods, such as crops and fermented foods; most glucosylceramides are not degraded or absorbed in the small intestine and pass through the large intestine. Glucosylceramide exerts versatile effects on colon tumorigenesis, skin moisture, cholesterol metabolism, and improvement of intestinal microbes in vivo; however, the mechanism of action has not yet been fully elucidated.

The metabolites of cultured broth supplemented with glucosylceramide were significantly different from those of broth not treated with glucosylceramide. The number of Gram-positive bacteria was significantly increased upon the addition of glucosylceramide compared to the control. Glucosylceramide endows intestinal microbes with tolerance to secondary bile acids. This in vitro research has not yet been replicated in controlled human trials.

Because a decrease in fecal hardness leads to the prevention of constipation, it is hypothesized that dietary glucosylceramide may exert physiological effects partly by preventing constipation; studies have shown that antipsychotic-induced constipation can interfere with sphingolipid metabolism, choline metabolism, and the sphingolipid signaling pathway. However, these hypotheses should be verified in future studies.

4.5 Metabolic Effects (Insulin Resistance, Glucose Metabolism)

In a model of fructose-induced insulin resistance in male Sprague Dawley rats, both sea-cucumber-derived glucosylceramides and ceramides significantly improved glucose tolerance, reduced the concentrations of serum glucose and glycosylated hemoglobin, and alleviated the accompanied hypertension. Ceramides significantly enhanced glycogen levels in skeletal muscle, whereas glucosylceramides significantly increased the hepatic glycogen levels. Glucosylceramides alleviated insulin resistance by inhibiting gluconeogenesis, promoting glycogen synthesis and insulin signal transduction in the liver.

This evidence is limited to animal models. Increased levels of endogenous glucosylceramides are associated with obesity-induced insulin resistance in mice and with neuronal deficits observed in neuronopathic Gaucher disease. The relationship between exogenous dietary glucosylceramide and metabolic outcomes in humans has not been established in clinical trials.

4.6 Gaucher Disease (Disease Context, Not Supplementation)

Gaucher disease provides important disease context because it is caused by insufficient activity of the enzyme that catabolizes glucosylceramide. Gaucher disease is an autosomal recessive inborn error of metabolism caused by loss of function mutations in the gene GBA1 that encodes lysosomal hydrolase β-glucocerebrosidase 1 in the lysosomes of the mononuclear phagocyte system; its major function is to cleave the β-glucosidic linkage of glucocerebroside lipids, including the hydrolysis of glucosylceramide into glucose and ceramide. In Gaucher disease, deficiency or mutation in this enzyme leads to aberrant accumulation of glucosylceramide primarily within the lysosome. This disease context underscores that glucosylceramide metabolism is centrally important to health, though supplementation with dietary glucosylceramide is distinct from the pathological accumulation seen in Gaucher disease.

4.7 Allergy and Immune Modulation

Studies evaluating the effect of dietary glucosylceramide from pineapple on type I hypersensitivity found that oral administration of pineapple-derived glucosylceramide inhibited ear edema in passive cutaneous anaphylaxis reaction; in a co-culture system, it inhibited β-hexosaminidase release from RBL-2H3 mast cells. This represents preclinical evidence only; controlled human data on allergy outcomes are not yet available.

5. Body Systems and Health Areas Associated with Glycosylceramides

Integumentary system (skin): The most strongly evidenced area of association; skin barrier function, TEWL reduction, hydration, and symptoms of dry or atopic skin. An increase in skin barrier function due to dietary sphingolipids was reported during the 2010s.
Gastrointestinal tract / Colonic epithelium: Intestinal barrier maintenance, modulation of colonic microbiota, potential inhibition of colon carcinogenesis in animal models. Sphingolipids including glucosylceramide are deeply implicated in intestinal health maintenance via the immune and nervous systems; intestinal impairments such as colon cancer and inflammatory bowel disease are becoming increasingly problematic pathologies.
Immune / Allergic responses: Preliminary evidence for modulation of mast cell degranulation and type I hypersensitivity via sphingoid base metabolites.
Metabolic system: Animal evidence for effects on glucose homeostasis and insulin sensitivity; not yet confirmed in humans.
Nervous system (disease context): Glucosylceramide accumulation in Gaucher disease is associated with neurological complications; relevance of dietary supplementation to neurological health has not been established.

6. Dosage Forms and Reported Dosages

Dosages used in clinical studies vary considerably by source material and formulation. The following are reported specifically in the primary literature:

Konjac extract (standardized to 5% glycosylceramides): 100 mg/day of the konjac extract (providing 5 mg glycosylceramides) in capsule form for 6 weeks in 51 healthy volunteers aged 18–60 years.
Wheat polar lipids complex (WPLC): 1.7 mg glucosylceramides and 11.5 mg of digalactosyldiglycerides per day, in oil or powder capsule form, for 60 days in 60 volunteers with dry and wrinkled skin.
Wine lees extract (WLE)-derived ceramides and glucosylceramides: The daily dose of the test supplement was 100 mg/day containing ≥2 mg WLE-derived ceramides and glucosylceramides, administered for 12 weeks.
Soy glucosylceramide (animal model): Soy GlcCer was added to the AIN-76A diet at 0.025 and 0.1% of the diet (wt/wt); at these levels it reduced colonic cell proliferation by 50–56% in DMH-treated mice.
Maize-extracted glucosylceramide (animal model): Hairless mice were fed a diet with or without a maize-extracted GluCer supplement for 5 weeks; dosing was reported as a dietary supplement percentage rather than an absolute dose.
General range reported in clinical literature: The doses studied are modest, typically 1–100 mg of ceramide-equivalent material per day; the trials show that small amounts are sufficient.

Most clinical studies measure improvements at 4–12 weeks of supplementation. Most clinical studies show measurable improvements after 4–12 weeks of consistent supplementation.

7. Safety Considerations and Notable Interactions

7.1 General Safety in Reported Trials

According to physician's assessments in one 12-week randomized controlled trial, no adverse events possibly linked to the test supplement were reported. No adverse events related to the supplements were reported; oral supplementation of wine lees extract-derived ceramides and glucosylceramides is described as a safe approach to enhancing skin barrier function. In the 2020 randomized study of oral konjac glucosylceramides at 100 mg/day over 6 weeks in 51 participants, the supplement group showed significant improvement with no adverse events reported. Across the available published clinical trials, safety signals are absent, but the studies are small (n = 30–100) and of short duration (6–12 weeks); no long-term safety data from controlled trials exist.

7.2 Wheat Allergy and Celiac Disease

Wheat-derived phytoceramides warrant scrutiny for those with celiac disease or wheat allergy; the extraction process removes nearly all gluten, bringing levels below 20 parts per million (the FDA threshold for "gluten-free" labeling), but products still carry wheat allergen warnings. Wheat-derived phytoceramides raise a legitimate allergen consideration for individuals with celiac disease or wheat sensitivity, though the extract is typically processed to remove gluten proteins; rice and konjac sources are naturally gluten-free and appropriate for this group.

7.3 Source-Dependent Allergen Risk

If someone has a true wheat allergy rather than gluten sensitivity, rice or konjac-based options are the safer choice. Soy-derived glucosylceramides present a consideration for individuals with soy allergy. Sea cucumber-derived preparations are marine-derived and should be evaluated accordingly for shellfish-adjacent sensitivities, though sea cucumber is taxonomically a class of echinoderms, not a crustacean or mollusc.

7.4 Relationship to Gaucher Disease and Glucosylceramide Accumulation

In the context of Gaucher disease, the disease is an autosomal recessive disease caused by GBA1 mutations resulting in glucosylceramide accumulation in macrophages. There is no clinical evidence that dietary supplementation with exogenous glucosylceramides in healthy individuals produces pathological accumulation via this mechanism; the enzyme deficiency in Gaucher disease is distinct from the metabolic handling of dietary glucosylceramide in individuals with normal GCase1 function.

7.5 Interaction Considerations

No specific pharmacokinetic drug–nutrient interactions between dietary glucosylceramide supplements and pharmaceuticals have been formally described in the available peer-reviewed clinical literature. Theoretical considerations include:

Glucosylceramides are lipid-based molecules; consumption with food (particularly fat-containing meals) may enhance micellar solubilization and absorption.
Taking these lipid-based compounds with a meal may support optimal absorption.
Given that plant-derived glucosylceramides are extensively catabolized in the gastrointestinal tract prior to absorption, systemic pharmacokinetic interactions with drugs metabolized by cytochrome P450 enzymes are not expected based on currently available evidence, but this has not been formally studied.

7.6 Regulatory Status

Wheat- and rice-derived phytoceramides have been the subject of New Dietary Ingredient (NDI) notifications in the United States. One such notification concerned phyto-derived ceramides, a type of lipid which are constituents of sphingolipids, derived from either wheat or rice. In Japan, dietary glucosylceramide preparations are widely marketed as quasi-drug and health food products. No formal monograph has been issued by ESCOP, the German Commission E, USP, or the European Pharmacopoeia specifically for botanical glycosylceramide supplements as of the available literature reviewed.

8. Evidence Strength Summary

Skin hydration / barrier function (oral): Moderate evidence. Multiple small-to-medium randomized, double-blind, placebo-controlled trials in humans, consistent in direction, using wheat, konjac, and wine lees sources. Limitations: small samples, short durations, absence of large independent trials.
Atopic dermatitis: Preliminary/limited clinical evidence from small studies and case observations. Further well-controlled trials required.
Colon cancer prevention: Animal and in vitro evidence only. Neither human clinical trials nor epidemiologic studies have yet evaluated whether sphingolipids influence human colon cancer.
Gut microbiome modulation: Emerging in vitro evidence; human trials are absent.
Metabolic effects (insulin resistance): Animal evidence only; no human clinical trials conducted.
Allergy/immune modulation: Preclinical only; no human trials.

References

Condiciones de Salud

Condiciones de salud que Glicosilceramidas puede ayudar a apoyar.

EructosCientífico
Glycosylceramides are plant-derived ceramide precursors that improve skin hydration when taken orally. A randomized clinical study of Konjac-derived glucosylceramides demonstrated improved skin moisture and reduced dry skin discomfort. Orally administered glycosylceramides are hydrolyzed to ceramides in the intestine, absorbed, and distributed to the skin.

Sistemas Corporales

Sistemas corporales que Glicosilceramidas puede ayudar a apoyar.

No hay sistemas corporales disponibles.